● Recruiting

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Condition: Dry Age-related Macular Degeneration · Sponsor: Luxa Biotechnology, LLC

PhasePhase 1/Phase 2

Planned participants18

Who can joinAll sexes, 55 Years to no upper limit

Healthy volunteersNo

About this study

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

This description comes directly from the study's public registry record.

Talk to the study team

Jeffrey H Stern, M.D., Ph.D. · 05184371111 · jeffreystern@luxabiotech.com

Always discuss trial participation with your own doctor first.

Locations (3)

Retina Vitreous Associates Medical Group	Beverly Hills, California, United States	Recruiting
Spencer Center for Vision Research	Palo Alto, California, United States	Recruiting
University of Michigan Kellogg Eye Center	Ann Arbor, Michigan, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04627428